InMatrico®

Tissue-specific extracellular matrix kits and assays for predictive disease modeling and drug testing


Technology

Tissue-specific decellularized ECMs

Predictive results consistent with those in patients: TissueSpec® dECMs enable physiologically-relevant disease modeling and drug testing in matrico by providing the tissue-specific biochemical and mechanical ECM signals lacking in vitro.

Primary tissues

2eaa0be26c7a816260e302088497ec42 (1) (1)
Tissues are comprised of cells attached to ECM.

Tissue-specific dECMs

c2c2bbd5d58b7ca1ecfb5bb6d77c41e5 (1) (1)
Tissue decellularization (cell removal) yields tissue-specific decellularized ECM (dECM).

TissueSpec® dECM Kits

d4403d21f6131000b9e11ea573ca53a7 (1)
Decellularized ECM (dECM) is processed into dECM coating and hydrogel kits.
Primary tissues are decellularized using proprietary protocols to obtain tissue-specific decellularized ECMs (dECM), which are then processed into quality-controlled, ready-to-use TissueSpec® dECM Coating and Hydrogel Kits.

International Distributors

Explore the map to find distributors near you.
Created with Raphaël 2.1.0

News

Read more

JUN. 14, 2024

Xylyx Bio Awarded $2.26M NIH SBIR Grant from National Cancer Institute

Read more

April 5, 2022

Xylyx Bio collaboration reveals new insights into tumor drug resistance

Read more
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Sept. 2, 2021

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute